APG101: Phase II data

An open-label, international Phase II trial in 83 patients with GBM showed that weekly IV APG101 plus radiotherapy as second-line treatment met the primary endpoint of PFS rate at 6 months vs. radiotherapy alone. Apogenix said the endpoint was considered met if the percentage of patients who were progression free at 6 months was increased by 100%. No treatment-related adverse effects were reported. The trial enrolled patients with GBM who had suffered first or second relapses and who no longer responded to temozolomide. Data on secondary endpoints will be presented later this year. ...